Study of BGC515 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called BGC515 for people with advanced solid tumors, including mesothelioma and EHE, that have not responded to standard treatments. The drug works by targeting a specific cell signaling pathway (Hippo) that may be involved in cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of advanced cancer (like mesothelioma, EHE, or another solid tumor) that has not responded to standard treatment
- You are able to take care of yourself (ECOG performance score 0 or 1)
- You have at least one tumor that can be measured on scans
- You have not taken a TEAD inhibitor before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests an experimental drug, TYK-01054, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or control the cancer.
This trial tests an experimental drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific cell pathway (Hippo) that may be involved in tumor growth.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.